Advertisement

Topics

Quetiapine Induced Neuroplasticity in First-Episode Schizophrenic Patients

2014-07-24 14:19:57 | BioPortfolio

Summary

Aim of the study is to assess the effect of quetiapine treatment in neuroleptic naive, first-episode schizophrenic patients on aspects of functional and structural neuroplasticity assessed by means of transcranial magnetic stimulation and voxel-based morphometry. Main outcome measure is a change in gray matter density under quetiapine treatment from baseline to steady-state-treatment after 3 weeks.

Study Design

Control: Uncontrolled, Intervention Model: Single Group Assignment, Masking: Open Label

Conditions

Schizophrenia

Intervention

Quetiapine

Location

University of Regensburg, Department of Psychiatry
Regensburg
Germany
93053

Status

Recruiting

Source

University of Regensburg

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:19:57-0400

Clinical Trials [1078 Associated Clinical Trials listed on BioPortfolio]

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing or...

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia. The primary hypothesis is that quetiapine...

Quetiapine XR in Schizophrenic Patients

The purpose of the study is to determine the effect of Quetiapine in patients with schizophrenia induced by cannabis abuse.

Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia

we aim to examine whether a representative atypical antipsychotic, quetiapine, has different effects from conventional antipsychotics on the magnetic resonance spectroscopy (MRS) markers i...

A 4-Week, Randomized, Rater-Blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia

Sleep disorders have been recognized by psychiatrists as a range of important symptoms of schizophrenia, which often appear in the exacerbation period as a signal of relapse and increase t...

PubMed Articles [850 Associated PubMed Articles listed on BioPortfolio]

How long does the pharmacokinetic interaction between carbamazepine and quetiapine last after carbamazepine withdrawal?

Carbamazepine and quetiapine are drugs that are used as mood stabilizers in the treatment of bipolar disorders. A series of studies has shown that concurrent use of carbamazepine decreases quetiapine ...

The antipsychotic drug quetiapine stimulates oligodendrocyte differentiation by modulating the cell cycle.

Recent studies have revealed that oligodendrocyte differentiation deficits and de-myelination occur in the brains of schizophrenic patients. Cell cycle proteins play a critical role in modulating olig...

A positron emission tomography study of norepinephrine transporter occupancy and its correlation with symptom response in depressed patients treated with quetiapine XR.

Quetiapine is effective in treating depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD), but the mechanisms underlying its antidepressants effects are unknown. Norquetiapi...

Antioxidative Effect of Quetiapine on Acute Ultraviolet-B-Induced Skin and HaCaT Cell Damage.

Quetiapine is a new type of antipsychotic drug, with effective protection of pheochromocytoma PC12 cells from oxidative stress-induced apoptosis. Ultraviolet-B radiation can increase reactive oxygen s...

Increasing rates of quetiapine overdose, misuse, and mortality in Victoria, Australia.

Quetiapine is misused due to its anxiolytic and hedonic effects and has been associated with deliberate self-harm. This study analyzed quetiapine-related calls to the Victorian Poisons Information Cen...

Medical and Biotech [MESH] Definitions

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.

A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.

An obsolete concept, historically used for childhood mental disorders thought to be a form of schizophrenia.

A type of schizophrenia characterized by frequent incoherence; marked loosening of associations, or grossly disorganized behavior and flat or grossly inappropriate affect that does not meet the criteria for the catatonic type; associated features include extreme social withdrawal, grimacing, mannerisms, mirror gazing, inappropriate giggling, and other odd behavior. (Dorland, 27th ed)

More From BioPortfolio on "Quetiapine Induced Neuroplasticity in First-Episode Schizophrenic Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Schizophrenia
Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...


Searches Linking to this Trial